Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors

PHASE3CompletedINTERVENTIONAL
Enrollment

410

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

February 28, 2010

Study Completion Date

March 31, 2014

Conditions
Advanced Neuroendocrine Tumors of Pancreatic Origin
Interventions
DRUG

Everolimus

A 10-mg dose of everolimus was given by continuous oral daily dosing of two 5-mg tablets.

DRUG

Everolimus Placebo

a 10-mg dose of matching placebo to Everolimus was given by continuous oral daily dosing of two 5-mg tablets.

Trial Locations (82)

112

Novartis Investigative Site, Taipei

807

Novartis Investigative Site, Kaohsiung City

1070

Novartis Investigative Site, Brussels

1200

Novartis Investigative Site, Brussels

3000

Novartis Investigative Site, Leuven

8091

Novartis Investigative Site, Zurich

10002

Novartis Investigative Site, Taipei

10032

Columbia University Medical Center- New York Presbyterian Dept. of Columbia Med. Center, New York

10400

Novartis Investigative Site, Bangkok

13353

Novartis Investigative Site, Berlin

13385

Novartis Investigative Site, Marseille

15213

University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh

20132

Novartis Investigative Site, Milan

20141

Novartis Investigative Site, Milan

20162

Novartis Investigative Site, Milan

21079

Novartis Investigative Site, Dijon

25030

Novartis Investigative Site, Besançon

28203

Levine Cancer Institute, Charlotte

31054

Novartis Investigative Site, Toulouse

33305

Novartis Investigative Site, Lin-Ko

33612

H. Lee Moffitt Cancer Center & Research Institute Malignant Hematology Clinic, Tampa

34298

Novartis Investigative Site, Montpellier

35033

Novartis Investigative Site, Marburg

36688

University of South Alabama / Mitchell Cancer Institute Deptof Mitchell Cancer Inst(2), Mobile

40138

Novartis Investigative Site, Bologna

40202

University of Louisville / James Graham Brown Cancer Center SC, Louisville

41100

Novartis Investigative Site, Modena

43210

Ohio State Comprehensive Cancer Center/James Cancer Hospital Dept. of OHSU Medical Center, Columbus

46202

Indiana University Health Goshen Center for Cancer Dept. of Indiana Univ. Cancer, Indianapolis

48201

Wayne State University/Karmanos Cancer Institute Dept.of KarmanosCancerInst (4), Detroit

51092

Novartis Investigative Site, Reims

52242

University of Iowa Medical Center Dept. of Iowa Medical Center, Iowa City

55131

Novartis Investigative Site, Mainz

55905

Mayo Clinic - Rochester, Rochester

56124

Novartis Investigative Site, Pisa

59020

Novartis Investigative Site, Lille

67098

Novartis Investigative Site, Strasbourg

69437

Novartis Investigative Site, Lyon

70115

LSU HEALTH SCIENCES CENTER/ LSU SCHOOL OF MEDICINE Dept. of Neuroendocrine Clinic, New Orleans

75015

Novartis Investigative Site, Paris

75651

Novartis Investigative Site, Paris

76104

The Center for Cancer and Blood Disorders, Fort Worth

81377

Novartis Investigative Site, München

90048

Cedars Sinai Medical Center SC-2, Los Angeles

90095

University of California at Los Angeles UCLA (3), Los Angeles

90110

Novartis Investigative Site, Songkhla

92110

Novartis Investigative Site, Clichy

92801

Pacific Cancer Medical Center, Inc., Anaheim

94805

Novartis Investigative Site, Villejuif

97239

Oregon Health & Science University Dept. of OHSU (3), Portland

99438

Novartis Investigative Site, Bad Berka

94143-0128

University of California San Francisco Dept. of UCSF Comp. Cancer, San Francisco

Unknown

Kaiser Permanente Northwest Franklin Medical Offices, Denver

St. Luke's Hospital and Health Network St. Luke's Cancer Network, Bethlehem

Novartis Investigative Site, Kashiwa

Novartis Investigative Site, Chuo-ku

02118

Boston Medical Center BMC, Boston

03561

Littleton Regional Hospital Dept. of Hematology/Oncology, Littleton

19111-2497

Fox Chase Cancer Center, Philadelphia

77030-4009

University of Texas/MD Anderson Cancer Center Dept of MD Anderson CancerCent, Houston

60430-370

Novartis Investigative Site, Fortaleza

T2N 4N2

Novartis Investigative Site, Calgary

T6G 1Z2

Novartis Investigative Site, Edmonton

N6A 4L6

Novartis Investigative Site, London

H1T 2M4

Novartis Investigative Site, Montreal

H3A 1A1

Novartis Investigative Site, Montreal

115 27

Novartis Investigative Site, Athens

GR-115 22

Novartis Investigative Site, Athens

812-8582

Novartis Investigative Site, Fukuoka

9713 GZ

Novartis Investigative Site, Groningen

036 59

Novartis Investigative Site, Martin

110 744

Novartis Investigative Site, Seoul

120-752

Novartis Investigative Site, Seoul

135-710

Novartis Investigative Site, Seoul

738-736

Novartis Investigative Site, Seoul

08035

Novartis Investigative Site, Barcelona

08907

Novartis Investigative Site, L'Hospitalet de Llobregat

SE-751 85

Novartis Investigative Site, Uppsala

M20 4BX

Novartis Investigative Site, Withington

G12 0YN

Novartis Investigative Site, Glasgow

EC1A 7BE

Novartis Investigative Site, London

SE5 9RS

Novartis Investigative Site, London

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY